New US pharmaceutical tariffs may have ‘no immediate impact’ on drugmakers: DPM Gan
Drugmakers are ‘continuing to clarify’ to better understand the conditions and criteria tied to the new taxes
[SINGAPORE] The upcoming pharmaceutical tariffs imposed by the Trump administration may have “no immediate impact” on drugmakers as many could qualify for exemptions, said Deputy Prime Minister (DPM) Gan Kim Yong on Saturday (Sep 27).
“As I understand, many of them actually already have plans to invest (in the US), so tariffs may not have immediate impacts on their exports,” said DPM Gan, who is also the trade and industry minister.
At the same time, major drugmakers are also “continuing to clarify” with the Trump administration to better understand the conditions and criteria tied to the new tariffs, he added.
These discussions include clarifying if plants that are in the process of planning would qualify for the exemptions.
He was speaking to reporters a day after US President Donald Trump announced a 100 per cent tariff on imports of branded or patented pharmaceutical goods from Oct 1, unless a company has already begun construction of a plant in the country.
Pharmaceutical firms that have broken ground on US facilities will receive exemptions, Trump said.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
The tariffs – and the associated exemptions – are significant to Singapore because pharmaceutical exports to the US account for about S$4 billion of the Republic’s exports, or about 13 per cent of domestic goods exports, to the country, noted DPM Gan.
A large share of these exports consists of patented, branded medicines that would be covered by the new tariffs.
Singapore also hosts nine of the world’s top 10 pharmaceutical firms.